Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Andrew Berens, the most common co-covered peer. Each carries 1 original source on average. We currently track 1 Healthcare story that mention Celcuity Inc., all published on July 20, 2026.
Last mentioned: Jul 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Andrew Berens, the most common co-covered peer. Each carries 1 original source on average. We currently track 1 Healthcare story that mention Celcuity Inc., all published on July 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Celcuity Inc.. Shared-story counts are live from our verified record — not editorial picks.
Pomerantz LLP probes Celcuity after FDA-approved breast cancer therapy Revtorpyk sees delayed Q3 2026 commercial launch, sending shares down 17.6%. Analysts question prior launch readiness; health investors weigh biotech regulatory and execution risks.
Source: prnewswire.com
Celcuity Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
